ANSWER: B

Rationale:

TRH binds a Gq-coupled G-protein-coupled receptor (GPCR) on pituitary thyrotroph cells. Gq activation stimulates phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate into two second messengers: inositol trisphosphate (IP3), which releases calcium from intracellular stores, and diacylglycerol (DAG), which activates protein kinase C. Together these signals drive both TSH synthesis and secretion. Understanding this mechanism is clinically relevant because dopamine and somatostatin, which tonically inhibit TSH secretion from the thyrotroph, act via separate pathways — dopamine via D2 receptors (Gi-coupled) and somatostatin via Gi-coupled receptors — explaining why high-dose dopamine infusions can suppress TSH and produce mild secondary hypothyroidism.

• Option A: Option A is incorrect because TRH does not act through a nuclear receptor; it is a peptide hormone that cannot cross the plasma membrane and acts exclusively through cell-surface receptors.
• Option C: Option C is incorrect because TRH does not bind a receptor tyrosine kinase; growth factors such as insulin and EGF use this receptor class, not hypothalamic releasing hormones.
• Option D: Option D is incorrect because TRH does not act through a ligand-gated ion channel; this receptor class is used by fast neurotransmitters such as acetylcholine at the neuromuscular junction and GABA at GABA-A receptors.
• Option E: Option E is incorrect because the TRH receptor is Gq-coupled, not Gs-coupled; TSH itself uses Gs (adenylyl cyclase/cAMP) signaling on thyroid follicular cells — not the pituitary thyrotroph — and confusing these two signaling steps is a common error.

ANSWER: D

Rationale:

The sodium-iodide symporter (NIS), encoded by the SLC5A5 gene and located on the basolateral membrane of thyroid follicular cells, uses the inward sodium gradient (maintained by Na/K-ATPase) to drive the uptake of iodide against its concentration gradient, cotransporting two sodium ions for each iodide ion. This concentrates iodide within the thyrocyte to 20–40 times the plasma level. Because NIS cannot distinguish between stable iodide and radioactive iodide isotopes, I-131 enters the thyroid by exactly the same mechanism. Once inside the gland, I-131 is incorporated into thyroglobulin and destroys thyroid tissue through local beta radiation — the basis for treatment of hyperthyroidism and differentiated thyroid cancer. NIS expression is upregulated by TSH and downregulated by excess iodide and by perchlorate, which competitively inhibits NIS and is used therapeutically in iodine-excess thyrotoxicosis.

• Option A: Option A is incorrect because iodide cannot passively diffuse across the basolateral membrane at physiologically relevant rates; active transport against a concentration gradient is required to achieve the 20–40-fold concentration within the cell.
• Option B: Option B is incorrect because NIS is sodium-coupled, not proton-coupled; proton-coupled transporters are found in gastrointestinal epithelium for amino acid and peptide absorption but are not the mechanism of thyroidal iodide uptake.
• Option C: Option C is incorrect because iodide transport is not mediated by endocytosis; endocytosis of colloid occurs during thyroid hormone secretion (bringing thyroglobulin in for proteolysis), not during iodide uptake.
• Option E: Option E is incorrect because pendrin is an iodide-chloride exchanger expressed on the apical membrane of the thyrocyte that moves iodide from the cytoplasm into the follicular lumen for organification — it does not mediate basolateral uptake from the bloodstream, which is NIS-dependent.

ANSWER: A

Rationale:

Thyroid peroxidase (TPO) is a heme-containing enzyme anchored to the apical membrane of the thyroid follicular cell, oriented toward the follicular lumen. Using hydrogen peroxide generated by DUOX2 (dual oxidase 2) as the oxidizing agent, TPO catalyzes two sequential and essential reactions: first, organification, in which iodide ions are oxidized and covalently attached to specific tyrosyl residues on thyroglobulin (Tg), a large dimeric glycoprotein (660 kDa) that serves as both the reaction scaffold and the storage matrix for thyroid hormones within follicular colloid — forming monoiodotyrosine (MIT, one iodine) and diiodotyrosine (DIT, two iodines); and second, coupling, in which two iodotyrosyl residues are oxidatively joined to form thyroxine (T4) from DIT+DIT, or triiodothyronine (T3) from DIT+MIT. Both thionamide drugs, methimazole and propylthiouracil (PTU), inhibit both of these TPO-mediated steps, which is why their onset of antithyroid effect is delayed — they cannot release stored hormone, they can only block new synthesis.

• Option B: Option B is incorrect because TPO does not transport iodide across membranes; iodide transport across the basolateral membrane is mediated by NIS, and transport across the apical membrane involves pendrin and other channels — not TPO.
• Option C: Option C is incorrect because thyroglobulin does not require phosphorylation as a precondition for iodination; its tyrosyl residues are directly available for TPO-mediated organification without prior modification.
• Option D: Option D is incorrect because TPO does not cleave thyroglobulin; proteolytic release of T4 and T3 from thyroglobulin occurs in lysosomes after TSH-driven endocytosis of colloid, and is mediated by lysosomal proteases, not by TPO.
• Option E: Option E is incorrect because TPO does not convert T4 to T3; that conversion is performed by deiodinase enzymes (primarily D1 and D2) in peripheral tissues and in the pituitary, not within the thyroid follicle by TPO.

ANSWER: C

Rationale:

The pituitary thyrotroph is unusually rich in type 2 deiodinase (D2), the enzyme that converts T4 to the more potent T3 by removing an iodine atom from the outer ring (5'-deiodination). This means that the pituitary generates its own local supply of T3 from circulating T4, independently of peripheral T3 production. As a result, TSH suppression tracks circulating T4 levels very closely: even a small rise in T4 increases intrapituitary D2-generated T3, which binds TRbeta2 receptors on the thyrotroph and suppresses TSH secretion. This explains why TSH is the most sensitive clinical marker of thyroid hormone adequacy on levothyroxine therapy — a TSH within the reference range confirms sufficient T3 signal at the pituitary, even when measuring only T4. It also explains why a persistently elevated TSH on stable levothyroxine almost always means inadequate T4 delivery (underdosing or absorption problem), not a failure of peripheral deiodination.

• Option A: Option A is incorrect because the pituitary thyrotroph does not produce TRH; TRH is secreted exclusively from the hypothalamic paraventricular nucleus, and a thyrotroph-to-hypothalamus short loop does exist in a general sense but does not operate by converting TSH to TRH.
• Option B: Option B is incorrect because T4 does not have a direct binding site on the TSH receptor; the TSH receptor is a glycoprotein hormone receptor that binds the TSH glycoprotein, not thyroid hormones.
• Option D: Option D is incorrect because TSH does not contain an iodinated tyrosine residue subject to deiodination; TSH is a glycoprotein whose bioactivity is modulated by its carbohydrate side chains, not by iodination.
• Option E: Option E is incorrect because T3 has approximately 3–4 times the receptor affinity of T4 at nuclear thyroid hormone receptors; T4 is the prohormone and T3 is the more potent active form, and this preference for T3 applies in the pituitary as in all other tissues.

ANSWER: E

Rationale:

Oral levothyroxine absorption occurs predominantly in the jejunum and upper ileum and is highly variable. Under ideal fasting conditions, bioavailability is approximately 70–80%, but this falls substantially in the presence of food (particularly coffee and high-fiber foods), elevated intragastric pH (from proton pump inhibitors or achlorhydria), intestinal malabsorption disorders (celiac disease, inflammatory bowel disease), and co-administered drugs that bind levothyroxine in the gastrointestinal lumen. Patients who do not take levothyroxine in a fasted state consistently show lower and more variable absorption, often requiring higher doses to maintain target TSH. The standard instruction is to take levothyroxine on an empty stomach, 30–60 minutes before the first meal of the day, or alternatively at bedtime at least 3 hours after the last meal. Liquid levothyroxine solution and soft gelatin capsule formulations demonstrate improved bioavailability because they do not require tablet dissolution and are less sensitive to intragastric pH.

• Option A: Option A is incorrect because levothyroxine does not have near-complete bioavailability; the 70–80% figure applies only under ideal fasting conditions, and food and drug interactions substantially reduce absorption in clinical practice.
• Option B: Option B is incorrect because 20–30% bioavailability would be far too low to support once-daily dosing; the actual fasting bioavailability of approximately 70–80% is what makes weight-based dosing predictable.
• Option C: Option C is incorrect because levothyroxine absorption is primarily an intestinal phenomenon, not limited by first-pass hepatic metabolism; the major site of variability is gastrointestinal absorption, and levothyroxine undergoes relatively little first-pass metabolism before reaching systemic circulation.
• Option D: Option D is incorrect because taking levothyroxine with milk is counterproductive; calcium in milk forms insoluble complexes with levothyroxine in the gastrointestinal lumen and reduces absorption by approximately 30–40%, similar to the interaction with calcium carbonate supplements.

ANSWER: B

Rationale:

Approximately 70% of circulating T4 is bound to thyroxine-binding globulin (TBG), with additional binding to transthyretin (TTR) and albumin. Only the unbound fraction (approximately 0.02% of total T4) is biologically active and available for cellular uptake, deiodination, and feedback on the pituitary. Estrogen — whether endogenous (as in pregnancy) or exogenous (in oral contraceptives and hormone replacement therapy) — stimulates hepatic synthesis of TBG and reduces its sialylation-dependent clearance. This raises TBG levels, which initially binds more free T4. However, the pituitary immediately senses the small transient fall in free T4 and responds with a modest TSH increase, which drives the thyroid to secrete enough additional T4 to restore the free fraction to its physiological set point. The net result is a new steady state with elevated total T4, elevated TBG, a normal free T4, and a normal TSH — a euthyroid patient with a misleadingly abnormal total T4. This is why free T4 measurement (not total T4) is the correct test in patients with altered TBG.

• Option A: Option A is incorrect because estrogen does not directly stimulate the TSH receptor; the rise in total T4 reflects increased binding-protein capacity, not increased thyroid hormone production beyond what is needed to restore the free fraction.
• Option C: Option C is incorrect because OCPs do not inhibit TPO; TPO is an intracellular thyroid enzyme inhibited by thionamide drugs, not by sex hormones.
• Option D: Option D is incorrect because OCPs do not increase D1 activity; estrogen's principal effect on thyroid hormone pharmacokinetics is on TBG levels, not on deiodinase activity.
• Option E: Option E is incorrect because estrogen raises TBG, which increases the binding capacity and therefore pulls free T4 into bound T4; it does not displace T4 from TBG — that is the effect of drugs such as phenytoin, salicylates, and furosemide in high doses, which compete for TBG binding sites and transiently elevate free T4.

ANSWER: D

Rationale:

The Wolff-Chaikoff effect is the transient autoregulatory inhibition of thyroid organification (the TPO-mediated step in which iodide is incorporated into thyroglobulin) that occurs when the thyroid gland is acutely exposed to very high iodide concentrations. The mechanism involves the intracellular accumulation of iodide species that inhibit DUOX2-generated hydrogen peroxide production and directly impair TPO activity, effectively blocking new thyroid hormone synthesis within hours of iodide loading. This effect is exploited clinically in two ways: preoperative preparation of the hyperthyroid gland (Lugol's iodine for 7–10 days reduces gland vascularity and friability, making thyroidectomy safer), and in thyroid storm (iodide given at least one hour after a thionamide loading dose blocks ongoing hormone release while the thionamide blocks new synthesis). The thyroid escapes Wolff-Chaikoff inhibition after several days by downregulating NIS expression, reducing intracellular iodide accumulation and restoring organification — which is why iodide alone is never used as a long-term antithyroid treatment.

• Option A: Option A is incorrect because iodide does not inhibit TPO in the same manner as thionamides; thionamides are competitive enzyme inhibitors that bind at the active site, whereas the Wolff-Chaikoff effect is an autoregulatory response to iodide excess, not a pharmacological enzyme inhibition.
• Option B: Option B is incorrect because iodide does not antagonize the TSH receptor; its effect is downstream of TSH receptor signaling, acting directly on organification, and the reduction in gland vascularity observed after Lugol's solution is likely related to reduced hormone synthesis and secretion rather than TSH receptor antagonism.
• Option C: Option C is incorrect because the Wolff-Chaikoff effect does not involve upregulation of D3 within the thyroid; D3 activity in the thyroid is not acutely regulated by iodide loading, and the principal D3-upregulating contexts are severe illness, fetal development, and certain solid tumors.
• Option E: Option E is incorrect because iodide loading does not accelerate lysosomal thyroglobulin degradation; indeed, the Wolff-Chaikoff effect inhibits new hormone synthesis precisely because the thyroid cannot efficiently organify the accumulated iodide — the proteolytic release step requires prior endocytosis of colloid by TSH-driven mechanisms.

ANSWER: A

Rationale:

Thyroid hormone receptors (TRs) are encoded by two genes: THRA (producing TRalpha1 and TRalpha2) and THRB (producing TRbeta1 and TRbeta2). TRalpha1 is the principal transcriptionally active isoform in the heart, bone, and gastrointestinal (GI) tract. This tissue-specific predominance explains the characteristic features of thyrotoxicosis: excess T3 signaling through TRalpha1 in the heart drives sinus tachycardia, increased cardiac output, and the predisposition to atrial fibrillation; excess signaling in bone accelerates osteoclast-mediated bone resorption, reducing bone mineral density and increasing fracture risk over time; and excess signaling in the GI tract increases gut motility, producing the hyperdefecation and weight loss despite increased caloric intake that characterize symptomatic hyperthyroidism. Conversely, TRalpha1 deficiency (hypothyroidism at these sites) produces bradycardia, heart failure, and constipation. This isoform distribution is pharmacologically relevant: selective TRbeta agonists such as resmetirom are designed to activate hepatic TRbeta1 while sparing TRalpha1-mediated cardiac and bone effects.

• Option B: Option B is incorrect because TRbeta1 predominates in the liver, not the heart, bone, and GI tract; TRbeta1 at hepatic sites regulates cholesterol metabolism, which is why hypothyroidism produces hypercholesterolemia.
• Option C: Option C is incorrect because TRbeta2 predominates in the pituitary thyrotroph and hypothalamic TRH neurons — it is the isoform that mediates TSH negative feedback suppression — not in the heart, bone, or GI tract.
• Option D: Option D is incorrect because TRalpha2 lacks a functional ligand-binding domain and cannot be activated by thyroid hormone; it is a splice variant of THRA that may function as a weak dominant negative inhibitor of ligand-activated TR signaling.
• Option E: Option E is incorrect because TR isoform distribution is distinctly tissue-specific, which is the mechanistic basis for targeted thyroid hormone receptor pharmacology; uniform isoform expression would make tissue-selective agonism pharmacologically impossible.

ANSWER: C

Rationale:

The TSH-free T4 relationship is log-linear: the TSH axis behaves logarithmically while the free T4 axis is linear. This means that a relatively small proportional change in free T4 produces a very large change in TSH. Quantitatively, a twofold change in free T4 produces approximately a 100-fold change in TSH. This amplification is what makes TSH such a sensitive marker of thyroid status — small over- or under-replacements that barely change measurable free T4 can produce TSH values far outside the reference range. However, this log-linear compression also means that the absolute TSH value conveys important information about the magnitude of the underlying hormone deficit or excess: a TSH of 8 mIU/L reflects a relatively modest T4 deficiency, while a TSH of 80 mIU/L reflects a much larger deficiency, even though both values are equally "elevated" in categorical terms. Similarly, a suppressed TSH of 0.1 mIU/L carries different clinical implications depending on context — intentional TSH suppression in thyroid cancer management versus inadvertent overreplacement in a postmenopausal woman on standard doses.

• Option A: Option A is incorrect because the TSH-free T4 relationship is not linear; a TSH of 40 mIU/L does not represent twice the hormone deficit of a TSH of 20 mIU/L — the log-linear relationship means the actual free T4 difference between those two TSH values is much smaller than a proportional interpretation would suggest.
• Option B: Option B is incorrect because the log-linear relationship is precisely what makes TSH a reliable and sensitive marker, not an unreliable one; free T4 is measured as a complementary test in specific circumstances (pituitary disease, early thyroid failure, suspected nonthyroidal illness) but does not replace TSH as the primary marker.
• Option D: Option D is incorrect because suppressed TSH values do convey meaningful clinical information — distinguishing a mildly suppressed TSH (0.1–0.4 mIU/L) from a fully undetectable TSH (<0.01 mIU/L) is clinically significant for risk stratification of atrial fibrillation and bone loss.
• Option E: Option E is incorrect because the log-linear relationship means that two patients with the same TSH may have similar hormone status, but differences in free T4 at the same TSH can reflect altered TBG or other confounders that require clinical interpretation — TSH and free T4 are complementary, not interchangeable.

ANSWER: E

Rationale:

Sick euthyroid syndrome, also called nonthyroidal illness syndrome, is a pattern of abnormal thyroid function tests seen in critically ill patients that does not represent primary thyroid gland dysfunction. The key mechanism involves two simultaneous deiodinase shifts: type 3 deiodinase (D3), which is normally restricted to the placenta and fetal tissues but is upregulated in multiple peripheral tissues during critical illness, converts T4 to inactive reverse T3 (rT3) by inner-ring (5-) deiodination rather than to active T3; and type 1 deiodinase (D1), which normally generates circulating T3 from T4 and also clears rT3, is simultaneously downregulated. The result is low T3, elevated rT3, normal to low T4 (further reduced by decreased TBG synthesis in the liver), and a low or low-normal TSH (because hypothalamic TRH and pituitary TSH are also downregulated by inflammatory cytokines). This pattern is interpreted as an adaptive response that reduces metabolic demand in tissues already stressed by critical illness. Multiple randomized trials have failed to show a mortality benefit from levothyroxine administration in this setting, and some data suggest harm. The correct management is to treat the underlying illness and recheck thyroid function tests 4–6 weeks after recovery before concluding that permanent thyroid disease is present.

• Option A: Option A is incorrect because the TSH is only low-normal, not markedly suppressed as would be expected in central hypothyroidism, and starting levothyroxine in sick euthyroid syndrome is not indicated and may be harmful.
• Option B: Option B is incorrect because the pattern described — low T3, elevated rT3, low-normal TSH — is classic sick euthyroid syndrome, not amiodarone-induced thyrotoxicosis; type 2 amiodarone thyrotoxicosis would present with a suppressed TSH and elevated free T4 in a patient known to be on amiodarone.
• Option C: Option C is incorrect because primary overt hypothyroidism would produce a markedly elevated TSH (typically >10 mIU/L), not a low-normal TSH; the low TSH in this patient is inconsistent with primary thyroid failure.
• Option D: Option D is incorrect because subclinical hyperthyroidism produces a suppressed TSH with normal free T4 and T3; the low T3 and elevated rT3 in this patient are not features of hyperthyroidism and instead point directly to sick euthyroid syndrome.

ANSWER: B

Rationale:

Levothyroxine (synthetic T4) has an elimination half-life of approximately 6–7 days. Pharmacokinetic steady state — the point at which the rate of drug input equals the rate of elimination and plasma concentrations stabilize — is reached after four to five half-lives. For levothyroxine, this is 28–35 days, which is why the clinical standard is to recheck TSH no sooner than 4–6 weeks after any dose change. Checking TSH at 2 weeks after a dose adjustment captures the system in a non-equilibrium transitional state; the TSH reading at that point will not reflect the eventual steady-state hormone level and may lead to inappropriate over-adjustment — for instance, a TSH that appears normal at 2 weeks may still be falling at 6 weeks, resulting in inadvertent overtreatment if the dose is further increased based on the 2-week value. This same principle applies after any change in formulation, brand, or generic source, since bioavailability can differ by up to 12.5% between formulations even within the FDA-accepted bioequivalence window.

• Option A: Option A is incorrect because levothyroxine's half-life is not 6–8 hours — that description applies to liothyronine (T3), which has a much shorter half-life of 1–2 days; the 6–7 day half-life of levothyroxine is what makes once-daily dosing appropriate.
• Option C: Option C is incorrect because the long wait after a levothyroxine dose change is not due to the half-life of TSH itself; TSH has a relatively short half-life of approximately 1 hour in the circulation, so it responds quickly once T4 levels stabilize — the limiting factor is the time required for T4 to reach a new steady state.
• Option D: Option D is incorrect because levothyroxine does not require hepatic activation; it is the prohormone T4 that undergoes peripheral deiodination primarily by D1 and D2 to generate the active T3, and this conversion is ongoing and continuous, not a rate-limited activation step that takes weeks after a dose change.
• Option E: Option E is incorrect because pituitary TSH secretion begins responding to changes in T3 signaling rapidly — within hours to days of new T3 levels — but the system cannot reach its new equilibrium until T4 levels have fully stabilized at their new steady state, which takes four to five half-lives of levothyroxine.

ANSWER: D

Rationale:

Absorption interactions are the most commonly overlooked drug interactions with levothyroxine in clinical practice. Calcium carbonate (and calcium citrate) bind levothyroxine in the gastrointestinal lumen by forming insoluble calcium-T4 complexes that cannot be absorbed, reducing levothyroxine absorption by approximately 20–40%. Ferrous sulfate and other iron salts bind levothyroxine through a similar chelation mechanism, with comparable reductions in absorption. The interaction is entirely a luminal (pre-absorptive) phenomenon and is not related to enzyme induction, transporter competition, or altered pH. Other common absorption-impairing agents include aluminum-containing antacids, sucralfate, cholestyramine, colestipol, and sevelamer (a phosphate binder used in chronic kidney disease). Proton pump inhibitors (PPIs) reduce gastric acidity and impair dissolution of standard levothyroxine tablets, reducing absorption by 15–25%. The correct management for all of these interactions is not to increase the levothyroxine dose but to separate the timing — taking levothyroxine at least 4 hours before or after the interacting agent — which restores normal absorption without requiring a dose adjustment.

• Option A: Option A is incorrect because calcium carbonate and ferrous sulfate are not hepatic enzyme inducers; drugs that induce CYP enzymes (rifampin, phenytoin, carbamazepine) can increase levothyroxine clearance and require dose increases, but the mechanism in this case is pre-absorptive luminal binding, not accelerated metabolism.
• Option B: Option B is incorrect because calcium carbonate does not cause alkaline destruction of levothyroxine in the stomach; the mechanism is lumenal complex formation between calcium ions and the levothyroxine molecule, not pH-mediated chemical degradation.
• Option C: Option C is incorrect because levothyroxine absorption is not primarily mediated by OATP1A2 (organic anion-transporting polypeptide 1A2) — passive absorption across the intestinal epithelium predominates — and ferrous sulfate does not interact with levothyroxine via transporter competition but by direct ionic binding in the lumen.
• Option E: Option E is incorrect because calcium carbonate's effect on levothyroxine absorption is a luminal binding interaction, not an intracellular signaling event; the calcium from calcium carbonate tablets is largely in the gastrointestinal lumen during the absorption window and does not significantly alter intracellular signaling in intestinal epithelial cells at the concentrations achieved.

ANSWER: A

Rationale:

TRbeta2 is the thyroid hormone receptor isoform expressed almost exclusively in the pituitary thyrotroph and hypothalamic TRH neurons, where it is the principal mediator of the negative feedback suppression of TSH by T3. This isoform specificity is the pharmacological rationale for selective TRbeta agonism: resmetirom (approved by the FDA in 2024 for MASH) is a liver-targeted selective TRbeta agonist that activates hepatic TRbeta1 to stimulate fatty acid oxidation, reduce de novo lipogenesis, and lower LDL cholesterol — effects mediated by the same TRbeta1 isoform that dominates in the liver — while minimizing activation of TRalpha1 in the heart and bone. The distinction between TRbeta1 (liver-predominant, cholesterol/lipid regulation) and TRbeta2 (pituitary/hypothalamus, TSH feedback) is pharmacologically critical: resmetirom produces some degree of TSH suppression (reflecting TRbeta2 activation) but the key therapeutic benefit is hepatic TRbeta1 activation with reduced TRalpha1-mediated cardiac and skeletal side effects compared to non-selective thyroid hormone administration.

• Option B: Option B is incorrect because TRalpha1 does not mediate pituitary TSH negative feedback; TRalpha1 predominates in the heart, bone, and GI tract — not the pituitary — and TRalpha1-selective drugs would be expected to produce cardiac and musculoskeletal effects rather than selective pituitary suppression.
• Option C: Option C is incorrect because TRbeta1, while abundantly expressed in the liver, is not the primary pituitary isoform mediating TSH feedback; TRbeta2 is the pituitary-predominant isoform, though TRbeta1 and TRbeta2 are co-expressed in some pituitary cells.
• Option D: Option D is incorrect because TRalpha2 lacks a functional ligand-binding domain and cannot be activated by T3, T4, or any thyroid hormone receptor agonist; it is a non-ligand-binding splice variant that may function as a weak dominant negative but is not a tractable drug target.
• Option E: Option E is incorrect because thyroid hormone receptor isoforms are distinctly distributed across tissues in a tissue-specific pattern, which is the fundamental basis for the entire field of selective thyroid receptor pharmacology; if all isoforms contributed equally to TSH feedback, the tissue-selective actions of drugs like resmetirom would be pharmacologically impossible.

ANSWER: C

Rationale:

Both PTU and methimazole inhibit thyroid peroxidase (TPO) and thereby block new thyroid hormone synthesis; neither drug releases stored thyroid hormones or reverses already-circulating hormone levels. The key distinguishing pharmacological property of PTU in the acute setting of thyroid storm is its additional inhibition of type 1 deiodinase (D1) in peripheral tissues — the enzyme responsible for the outer-ring (5'-) deiodination of T4 to the more potent T3. In thyroid storm, circulating T4 levels are high and rapid peripheral conversion to T3 amplifies the crisis. By blocking D1 in addition to TPO, PTU reduces ongoing T4-to-T3 conversion in peripheral tissues (particularly the liver and kidney), producing a faster fall in circulating T3 than TPO inhibition alone. This dual mechanism is why PTU is preferred over methimazole in thyroid storm. Propranolol also inhibits D1 at high doses and is used concurrently in thyroid storm for this additional reason beyond its beta-blocking properties. Note that for chronic management of hyperthyroidism outside of pregnancy and thyroid storm, methimazole is generally preferred over PTU because of PTU's risk of severe hepatotoxicity (rare but potentially fatal) and its shorter duration of action requiring more frequent dosing.

• Option A: Option A is incorrect because PTU does not have a faster onset of gastrointestinal absorption than methimazole; both are rapidly absorbed, and the advantage of PTU is not related to pharmacokinetic differences in absorption but to its additional D1 inhibitory effect.
• Option B: Option B is incorrect because both PTU and methimazole inhibit TPO reversibly, not irreversibly; thionamide inhibition of TPO does not involve covalent bond formation with the enzyme active site and reverses when drug concentrations fall.
• Option D: Option D is incorrect because PTU actually has a shorter half-life than methimazole (PTU approximately 1–2 hours versus methimazole approximately 4–6 hours), requiring more frequent dosing, not less — this is one reason methimazole is preferred for chronic management outside of the specific indications for PTU.
• Option E: Option E is incorrect because PTU's advantage in thyroid storm relates to peripheral D1 inhibition, not central nervous system penetration; the CNS manifestations of thyroid storm resolve as systemic T3 levels fall, not through direct central drug effects.

ANSWER: E

Rationale:

Liothyronine (synthetic L-triiodothyronine, T3) has an oral bioavailability of approximately 95% (higher than levothyroxine's 70–80%) but a dramatically shorter elimination half-life of approximately 1–2 days compared to levothyroxine's 6–7 days. This pharmacokinetic profile creates both advantages and disadvantages. The short half-life means conventional twice- or three-times-daily oral dosing produces marked serum T3 peaks after each dose with troughs in between, creating a pulsatile pharmacodynamic profile that does not mimic the stable circulating T3 levels that peripheral deiodination of T4 generates; this is one reason routine hypothyroidism management prefers levothyroxine monotherapy. However, the short half-life confers two specific clinical advantages: (1) in myxedema coma (severe hypothyroid encephalopathy requiring urgent thyroid hormone restoration), IV liothyronine provides more rapid central nervous system reactivation than levothyroxine because T3 does not require peripheral deiodination before receptor binding; and (2) in thyroid cancer surveillance requiring total-body I-131 scanning, liothyronine's shorter half-life allows a shorter hormone withdrawal period (3–4 weeks off liothyronine) to achieve the TSH elevation needed to stimulate NIS expression in residual thyroid tissue, compared to the 6–8 week withdrawal required for levothyroxine.

• Option A: Option A is incorrect because liothyronine does not have a 6–7 day half-life; that describes levothyroxine, and liothyronine's short half-life of 1–2 days is precisely what distinguishes its clinical profile.
• Option B: Option B is incorrect because liothyronine does not have a half-life of 3–4 weeks; this is a fabricated value, and liothyronine is less protein-bound than levothyroxine (which accounts in part for its shorter half-life and more rapid onset), not more bound.
• Option C: Option C is incorrect because liothyronine's half-life is not 30–40 minutes; such a very short half-life would require constant infusion, which is not how liothyronine is used clinically; it is given by intermittent IV bolus or oral dosing, with the 1–2 day half-life providing clinically useful duration of action.
• Option D: Option D is incorrect because liothyronine has approximately 95% oral bioavailability, not 50%; it is actually more completely absorbed than levothyroxine, and its pharmacokinetic disadvantages for routine use stem from the short half-life causing peaks and troughs, not from poor bioavailability.

ANSWER: B

Rationale:

Amiodarone contains approximately 37% iodine by weight and exerts multiple effects on thyroid hormone physiology that produce a characteristic and predictable biochemical signature in the first weeks to months of therapy. The expected early changes include: competitive inhibition of type 1 deiodinase (D1), which reduces T4-to-T3 conversion and simultaneously reduces rT3 clearance, producing elevated free T4 and elevated rT3 while circulating T3 falls; displacement of T4 from thyroxine-binding globulin (TBG) binding sites, contributing to the rise in free T4; and transient TSH elevation of up to 2–3 times the upper reference limit due to the fall in T3 signaling at the pituitary. This pattern within the first 3 months of amiodarone initiation reflects the drug's pharmacological effects on deiodinase activity and protein binding — not thyroid disease. After 3 months, persistent TSH elevation beyond 2–3× the upper reference limit indicates amiodarone-induced hypothyroidism; a suppressed TSH with elevated free T4 after 3 months indicates amiodarone-induced thyrotoxicosis requiring differentiation between type 1 (iodine-excess driven new synthesis, treated with thionamides plus perchlorate) and type 2 (destructive thyroiditis, treated with glucocorticoids). This patient's 6-week pattern is the expected drug effect — no thyroid intervention is warranted.

• Option A: Option A is incorrect because type 1 amiodarone thyrotoxicosis presents with a suppressed TSH, not a mildly elevated TSH; the mildly elevated TSH at 6 weeks is an expected transient drug effect, not a sign of thyrotoxicosis.
• Option C: Option C is incorrect because type 2 amiodarone thyrotoxicosis presents with a suppressed TSH and elevated free T4, not a mildly elevated TSH; this patient's TSH of 6 mIU/L is elevated, not suppressed, pointing to a hypothyroid tendency, not a thyrotoxic one.
• Option D: Option D is incorrect because although amiodarone's iodide load can trigger the Wolff-Chaikoff effect and cause hypothyroidism in susceptible individuals, the TSH of 6 mIU/L at 6 weeks is within the range expected as a transient drug effect and does not yet indicate established hypothyroidism requiring levothyroxine; persistent TSH elevation beyond 3 months would prompt intervention.
• Option E: Option E is incorrect because the pattern of elevated free T4 with a mildly elevated TSH is not physiologically impossible in the context of amiodarone; it is pharmacologically explained by D1 inhibition (raising T4) combined with reduced T3-mediated pituitary feedback (producing TSH elevation), and is one of amiodarone's well-documented early thyroid effects.

ANSWER: D

Rationale:

Type 1 deiodinase (D1), encoded by the DIO1 gene, is expressed at highest levels in the liver, kidney, thyroid gland, and skeletal muscle. D1 performs outer-ring (5'-) deiodination, removing an iodine atom from the outer phenol ring of T4 to generate the more biologically active T3 — this accounts for a substantial proportion of circulating T3 production. D1 also clears reverse T3 (rT3) from the circulation by deiodinating it to inactive diiodothyronine (T2). This dual role — generating active T3 and clearing inactive rT3 — means that D1 inhibition raises rT3 while lowering circulating T3. D1 is inhibited by propylthiouracil (PTU), which is one reason PTU has an advantage over methimazole in thyroid storm (blocking both new hormone synthesis via TPO inhibition and peripheral T4-to-T3 conversion via D1 inhibition). Amiodarone and high-dose propranolol also inhibit D1, which accounts for the elevated rT3 and reduced T3 seen with amiodarone therapy and for the modest T3-lowering effect sometimes exploited with propranolol in thyrotoxicosis management.

• Option A: Option A is incorrect because the description matches type 2 deiodinase (D2), not D1; D2 is the isoform expressed in the pituitary, brain, brown adipose tissue, and heart that provides intracellular T3 for local feedback and thermogenesis, and D2 is not expressed in the liver.
• Option B: Option B is incorrect because performing only inner-ring deiodination (generating rT3) is the function of type 3 deiodinase (D3), not D1; D1 performs outer-ring (5'-) deiodination as its primary function to generate T3, and also clears rT3.
• Option C: Option C is incorrect because the fetal and placental isoform that protects developing tissues from active T3 is D3, which is expressed at very high levels in the placenta and fetal liver and brain during neurodevelopment; D1 is not the fetal protective deiodinase.
• Option E: Option E is incorrect because the description of a brain- and heart-predominant isoform that is upregulated in hypothyroid states matches D2, not D1; D2 upregulation in hypothyroid states (and downregulation when T4 is high) is the homeostatic buffering mechanism that maintains intracellular T3 in D2-expressing tissues across a range of circulating T4 levels.

ANSWER: A

Rationale:

Thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily. Unlike glucocorticoid receptors, which reside in the cytoplasm until ligand binds and then translocate to the nucleus, TRs are constitutively located in the nucleus and are pre-bound to thyroid hormone response elements (TREs) — specific DNA sequences in the promoters of target genes — even in the absence of ligand. In the unliganded state, TRs recruit nuclear corepressor proteins NCoR1 (nuclear receptor corepressor 1) and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor). These corepressors recruit histone deacetylase (HDAC) complexes, which remove acetyl groups from histone tails, condensing chromatin structure and preventing transcription of target genes. When T3 binds to the ligand-binding domain of TR, it induces a conformational change (rotation of helix 12 in the ligand-binding domain) that displaces corepressors and creates a new surface that attracts coactivator proteins — including SRC-1 (steroid receptor coactivator 1) and other p160 family members. Coactivators recruit histone acetyltransferases (HATs), which acetylate histones, open chromatin, and enable assembly of the general transcription machinery. This corepressor-to-coactivator switch is the molecular basis for the transition from transcriptional silencing to transcriptional activation.

• Option B: Option B is incorrect because this describes the classic glucocorticoid receptor mechanism (cytoplasmic retention by HSP90, ligand-induced nuclear translocation); TRs do not require ligand binding to enter the nucleus and are not retained by heat shock proteins — they reside constitutively in the nucleus and act as transcriptional repressors in the unliganded state.
• Option C: Option C is incorrect because it reverses the actual mechanism; unliganded TRs are pre-bound to corepressors (not coactivators), and T3 binding releases those corepressors and recruits coactivators — not the other way around.
• Option D: Option D is incorrect because T3 does bind directly to the ligand-binding domain of nuclear TR; the genomic mechanism described in Option A (direct nuclear receptor binding) is the primary mechanism for thyroid hormone gene regulation, and while non-genomic T3 signaling via cytoplasmic TR or membrane integrins exists, it does not involve PLC activation as the route to genomic effects.
• Option E: Option E is incorrect because TRs are nuclear receptors, not membrane receptors or plasma protein-bound receptors; TBG binds T4 and T3 in the bloodstream as transport proteins, not as receptors, and the free fraction of T3 that enters cells does so by passive diffusion and specific transporters (including MCT8), not by binding to TBG-associated TR complexes.

ANSWER: C

Rationale:

Rifampin is the most potent hepatic enzyme inducer in routine clinical practice. It acts by activating the pregnane X receptor (PXR) — a ligand-activated nuclear receptor that functions as a xenobiotic sensor, upregulating the transcription of multiple drug-metabolizing enzymes and transporters. The relevant enzymes for thyroid hormone metabolism are CYP3A4, the UGT family (particularly UGT1A4 and UGT2B7), and the sulfotransferase (SULT) family, which glucuronidate and sulfate T4 and T3, producing water-soluble conjugates excreted in bile (with some enterohepatic recycling). Rifampin induction of these pathways substantially increases T4 and T3 clearance, reducing circulating thyroid hormone levels and driving a compensatory TSH rise as the pituitary detects the fall in free T4. Patients on stable levothyroxine who start rifampin for tuberculosis will typically develop a rising TSH within weeks and usually require dose increases of 20–50% or more to maintain euthyroidism. The same principle applies to other PXR-activating enzyme inducers: phenytoin, carbamazepine, phenobarbital, and to a lesser degree some SSRIs.

• Option A: Option A is incorrect because rifampin does not inhibit NIS in the gastrointestinal tract; NIS is a thyroidal transporter (and is also expressed in breast and salivary gland) but is not the mechanism of levothyroxine intestinal absorption, which occurs by passive and facilitated diffusion — and rifampin has no pharmacological effect on NIS.
• Option B: Option B is incorrect because rifampin does not induce TBG synthesis; rifampin is a PXR activator, and PXR activation upregulates phase I and phase II metabolizing enzymes, not plasma binding proteins — TBG synthesis is regulated by estrogen and other hormones, not by PXR.
• Option D: Option D is incorrect because rifampin does not inhibit type 2 deiodinase (D2); D2 inhibition is performed by drugs such as amiodarone and PTU, not by rifampin, whose pharmacological effects on thyroid hormone metabolism are entirely through accelerated conjugative metabolism.
• Option E: Option E is incorrect because levothyroxine is synthetic L-thyroxine — a complete hormone molecule — and rifampin does not chelate iodine; the levothyroxine molecule is absorbed intact and does not release iodine in the gastrointestinal lumen for rifampin to bind.

ANSWER: E

Rationale:

Type 2 deiodinase (D2), encoded by the DIO2 gene, is the primary source of intracellular T3 in D2-expressing tissues including the brain, pituitary, brown adipose tissue, heart, and skeletal muscle. The DIO2 gene contains a common functional single-nucleotide polymorphism (rs225014) that substitutes alanine for threonine at position 92 of the protein (Thr92Ala). The Ala92 variant has reduced catalytic efficiency compared to the Thr92 wild type, meaning that D2-expressing cells in carriers convert T4 to T3 less efficiently. In the brain, which depends heavily on D2-generated intracellular T3 for neuronal function, homozygous Ala92 carriers may generate suboptimal intracellular T3 even when circulating T4 is within the normal range on levothyroxine therapy — because the peripheral conversion that generates circulating T3 is D1-mediated, not D2-mediated, and does not compensate for impaired intracellular D2 activity in neurons. This provides a molecular rationale for why some patients report persistent symptoms of hypothyroidism despite TSH-optimized levothyroxine monotherapy, and for trials of combination T4/T3 therapy in this population — bypassing the D2 bottleneck by providing pre-formed T3. However, randomized controlled trials of combination therapy have produced inconsistent results, and American Thyroid Association guidelines recommend levothyroxine monotherapy as the first-line approach, with combination therapy reserved for a carefully considered trial in persistently symptomatic patients.

• Option A: Option A is incorrect because Thr92Ala affects D2 (type 2 deiodinase), not D3 (type 3 deiodinase); D3 inactivates T3 rather than activates it, and reduced D3 activity would increase T3, not impair it.
• Option B: Option B is incorrect because Thr92Ala is a DIO2 polymorphism affecting deiodinase enzyme activity, not a receptor polymorphism; it does not alter TRbeta2 expression or pituitary TSH sensitivity.
• Option C: Option C is incorrect because DIO2 encodes type 2 deiodinase, not NIS; NIS is encoded by SLC5A5 and mediates thyroidal iodide uptake, which is an entirely separate system from peripheral T4-to-T3 conversion.
• Option D: Option D is incorrect because DIO2 encodes a deiodinase enzyme, not a TBG regulator; TBG expression is regulated by estrogen and other hormones and is not affected by the DIO2 Thr92Ala variant.

ANSWER: B

Rationale:

Under basal conditions, the thyroid gland secretes approximately 80–100 mcg of thyroxine (T4) and only approximately 5–10 mcg of triiodothyronine (T3) per day. Because T3 has approximately 3–4 times the receptor affinity of T4 and is the biologically active form at the level of the nuclear receptor, and because the gland secretes primarily T4, peripheral conversion by deiodinase enzymes is the dominant source of circulating T3. Approximately 80% of circulating T3 is generated by outer-ring (5'-) deiodination of T4 by type 1 deiodinase (D1) in the liver, kidney, thyroid, and skeletal muscle and by type 2 deiodinase (D2) in the pituitary, brain, brown adipose tissue, and heart. Only about 20% of circulating T3 is secreted directly by the thyroid gland. This quantitative relationship has important clinical implications: it means that adequate levothyroxine (T4) replacement, by providing substrate for peripheral deiodination, is sufficient to generate normal circulating T3 in most patients — which is why levothyroxine monotherapy is the standard of care for hypothyroidism. It also means that peripheral T4-to-T3 conversion can be disrupted by D1 inhibitors (amiodarone, PTU, high-dose propranolol) and by severe illness (sick euthyroid syndrome), lowering T3 without any change in thyroid gland function.

• Option A: Option A is incorrect because T4 and T3 are not secreted in equal amounts; T4 is the dominant secretory product at roughly 80–100 mcg/day compared to only 5–10 mcg T3/day.
• Option C: Option C is incorrect because T3 is not the dominant secretory product of the thyroid; T4 is secreted in far greater quantities, and T3 constitutes only a minor fraction of direct thyroid secretion under basal conditions.
• Option D: Option D is incorrect because the ratio of peripheral to direct thyroid T3 is approximately 80% peripheral and 20% direct under normal conditions — not 50/50 — and while peripheral deiodination is somewhat reduced in sick euthyroid syndrome (with D1 downregulated), the ratio does not shift to the values described.
• Option E: Option E is incorrect because the thyroid gland secretes approximately 80–100 mcg of T4 per day, not 300 mcg; and under normal physiological conditions, approximately 40–45% of T4 is converted to T3, approximately 30–45% to reverse T3, and the remainder undergoes sulfation and glucuronidation — the claimed 90% rT3 conversion does not reflect normal deiodinase physiology.

ANSWER: D

Rationale:

Amiodarone-induced thyrotoxicosis is a clinically important complication occurring in approximately 3–8% of patients on long-term amiodarone therapy in iodine-sufficient countries and requiring precise classification because the two types have different mechanisms and different treatments. Type 1 AIT occurs in patients with pre-existing underlying thyroid disease (autonomous nodular goiter or subclinical Graves' disease) in whom the massive iodide load from amiodarone (approximately 37% iodine by weight, releasing approximately 6 mg of free iodine per day against a normal dietary requirement of 150–200 mcg) drives autonomous new thyroid hormone synthesis — similar to the Jod-Basedow effect seen with iodinated contrast. Type 1 is treated with thionamides (methimazole or PTU) to block new hormone synthesis and perchlorate to competitively inhibit NIS and reduce further iodide uptake by the thyroid. Type 2 AIT occurs in a structurally normal thyroid gland, where direct amiodarone cytotoxicity and/or its metabolites cause follicular cell destruction and release of preformed thyroid hormones — a destructive thyroiditis. Type 2 does not involve new hormone synthesis, so thionamides are largely ineffective; the treatment is glucocorticoids (typically prednisone 40 mg/day) to suppress the inflammatory destructive process. Critically, amiodarone should not be discontinued without cardiology consultation given the risk of arrhythmia recurrence, and its 40–55 day half-life means that even if discontinued, iodine release from amiodarone stored in adipose tissue continues for months — so discontinuation alone does not resolve AIT promptly.

• Option A: Option A is incorrect because type 1 AIT is not autoimmune Graves' disease triggered by amiodarone — it involves iodine-driven autonomous synthesis in pre-existing abnormal thyroid tissue, not new autoimmunity — and RAI is inappropriate because the massive iodide load from amiodarone makes the gland poorly responsive to I-131.
• Option B: Option B is incorrect because it omits the critical safety caveat that amiodarone must not be discontinued without cardiology consultation — the drug's 40–55 day half-life means thyroid effects persist for months regardless of stopping the drug, and abrupt discontinuation carries serious arrhythmia risk; a clinically complete answer must include this management principle, which Option B lacks.
• Option C: Option C is incorrect because amiodarone's half-life is 40–55 days (not short), so discontinuation does not resolve thyrotoxicosis within 48 hours; persistent drug and iodine release from adipose stores means thyroid effects continue for months after discontinuation.
• Option E: Option E is incorrect because the two types of AIT require fundamentally different treatments — thionamides plus perchlorate for type 1 versus glucocorticoids for type 2 — and treating type 2 with methimazole alone is ineffective because type 2 involves release of preformed hormone from damaged follicles, not new synthesis that methimazole could block.